Adc Therapeutics Sa ADCT

$1.23 -0.03 (-2.38%)

Valuation

Market cap
160,862,000
Revenue TTM
$81,360,000
Net income TTM
$-142,620,000
PE ratio
0.00
Forward PE
—
Profit margin
-175.30%
Debt to equity
-0.51

Trading

Volume
781,000
Avg volume
1,429,260
Day's range
$1.20 – $1.29
Shares out
127,668,000
Stochastic %K
71%
Beta
1.84
Analysts
Sell
Price target
$3.33

Price

Company profile

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or ref...

Show more

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
41 21 653 02 00
Website
https://www.adctherapeutics.com
Address
BiopOle, Route de la Corniche 3B, Epalinges, Switzerland

Latest news

Stocktwits

JuggernautRaider Sep 24, 11:58 AM
$ADCT 🧐 I’m staying away but cheering on from a distance 🤫 hope it works out for all y’all 🤠 🇺🇸 🚀
0 replies
topstockalerts Sep 24, 2:21 AM
$ADCT the market seems reluctant to let this fade.
0 replies
Flying_Trader2 Sep 23, 4:31 PM
$ADCT ADCT is bucking strong down pressures in Bio's today... someone wants it...
0 replies
Teeebagtomm Sep 22, 6:37 PM
$ADCT and Inovio coming up on huge milestones. Both stocks already took a huge beating last few months.
0 replies
Play_Nice69 Sep 22, 3:34 PM
$ADCT https://www.morningstar.com/news/marketwatch/20260921249/these-beaten-down-stocks-could-bounce-back-in-january-if-history-is-any-guide
0 replies
fmalad Sep 19, 2:41 AM
$ADCT The LOTIS-7 readout is expected at ASH 2026, with the abstracts scheduled to be released November 4, 2026. ADC Therapeutics has confirmed that the LOTIS-7 abstract was submitted to ASH and that the full data will be presented at the meeting. Key dates for ADCT / LOTIS-7 * November 4, 2026: ASH abstracts released — this should give us the detailed LOTIS-7 efficacy and safety data. * ASH 2026 meeting: Full presentation of LOTIS-7 data. * 100 patients enrolled: The trial completed enrollment in June 2026. * Previous data: ZYNLONTA + glofitamab produced 89.8% ORR and 77.6% CR in the earlier 49-patient efficacy-evaluable group. 77.6% CR rate in the earlier cohort is the benchmark. If we naintain or are >75% we are off to the races. Keep in mind transplant cost is now approaching an average of 1.2 million per patient!
0 replies
Bigjohnson99 Sep 17, 3:25 PM
$ADCT 😂 this trash can’t gain $.05 with the XBI absolutely ripping?
0 replies
Rox22 Sep 16, 9:31 PM
$ADCT 3 million shares on 3% move isn't ”huge.” not even close to a liquidation event. gotta wait for clarity and data end of the year. at this price/market cap worth seeing what happens. risk/reward seems appropriate. down to a single asset. maybe a pop on lotis 7. i think managment is fatigued. good or bad lotis 7 i think they sell the company in next 1-2 years for the asset and IP. all depends on what they can get….
2 replies